Novel combination

Claim 2

A combination of t-PA and a prostaglandin which is PGE₁, or a pharmaceutically acceptable salt thereof, or a compound of formula (I). wherein R₁ is -(CH₂)₃COR₄ or in which R₄ is hydroxy, C 1-4 alkoxy, amino, C 1-4 alkylamino or di-C 1-4 alkylamino, R₂ is n-pentyl, cyclopentyl, cyclohexyl or 1-methyl-3-pentynyl, R₃ is hydrogen or methyl, and X is oxygen or methylene, or a pharmaceutically acceptable salt thereof.

Claim 3

A combination according to claim 1, wherein the t-PA is in the one-chain form.

Claim 4

A combination according to claim 1, wherein the t-PA is in the two-chain form.

Claim 5

A combination according to any one of the preceding claims, wherein the t-PA has the amino acid sequence set forth in Figure 1 or has the same amino acid sequence but with the amino acid in the 245th position from the serine N-terminus being valine instead of methionine, either sequence optionally being without any of the first three amino acids or optionally having an additional polypeptide N-terminal presequence of Gly-Ala-Arg.

Claim 6

A combination according to any one of the preceding claims, wherein the prostaglandin is PGE₁, or a pharmaceutically acceptable salt thereof, or a compound of formula (I), in which R₄ is hydroxy, or a pharmaceutically acceptable salt thereof.

Claim 7

A combination according to claim 5, wherein the prostaglandin is prostacyclin, or a pharmaceutically acceptable salt thereof.

Claim 8

A combination according to claim 5, wherein the prostaglandin is carbacylin, or a pharmaceutically acceptable salt thereof.

Claim 9

A combination according to claim 5 wherein the prostaglandin is 9-β-methylcarbacyclin, or a pharmaceutically acceptable salt thereof.

Claim 10

A combination according to claim 5, wherein the prostaglandin is iloprost, or a pharmaceutically acceptable salt thereof.

Claim 11

A combination according to claim 5, wherein the prostaglandin is a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R₁ is -(CH₂)₃COR₄ in which R₄ is hydroxy, R₂ is cyclopentyl, R₃ is hydrogen, and X is methylene.

Claim 12

A combination according to claim 5, wherein the prostaglandin is a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R₁ is in which R₄ is hydroxy, R₂ is cyclohexyl, R₃ is hydrogen, and X is methylene.

Claim 13

A pharmaceutical formulation, which comprises a combination according to any one of the preceding claims and a pharmaceutically accceptable carrier.

Claim 14

A combination acording to any one of claims 1 to 11 for use in human and veterinary medicine.

Claim 15

A combination according to claim 13 for use in removing or inhibiting the formation of a blood clot.

Claim 16

Use of a combination according to any one of claims 1 to 11 in the preparation of a medicament for removing or inhibiting the formation of a blood clot in a mammal.